title: Genotype-specific effects on left ventricular function in parvovirus B19-positive patients with dilated cardiomyopathy.
abstract: Genotype-specific effects of parvovirus B19 (B19V) infections on left ventricular function in patients with dilated cardiomyopathy (DCM) have not been investigated so far. In this prospective clinical study, the prevalences of B19V genotypes in endomyocardial biopsies from patients presenting with inflammatory heart disease and DCM were determined. A total of 139 consecutive patients were included in the study; among them 53 patients were diagnosed as DCM. Among the total study cohort, B19V DNA was detected in 65 study participants (46.8%). Genotyping of the B19V genomes in the total cohort identified genotype 1 in 38 samples (27.3%), genotype 2 in 25 samples (18.0%), and genotype 3 in only two patients (1.4%). During an average follow-up period of 8 months left ventricular ejection fraction (LVEF) improved significantly both in B19V-positive (7.1 ± 13.8%, n = 17, P = 0.038) as well as B19V-negative patients with DCM (9.5 ± 13.9%, n = 20, P = 0.017). However, mean LVEF improved only in patients with genotype 1 (11.0 ± 14.4%, n = 7), whereas it even decreased in patients with genotype 2 (-6.2 ± 6.3%, n = 5, P = 0.033). These data from a small sample of patients diagnosed as DCM suggested that myocardial function during short-time follow-up differed between genetic variants of B19V. Patients with genotype 1 were on average younger than genotype 2 and appeared to be more prone to a beneficial course of left ventricular function than patients with genotype 2. Future studies with larger sample sizes and longer follow-up periods will be required to confirm this observation.
authors.affiliation: Department of Cardiology, University Hospital Gießen & Marburg, Marburg, Germany.
authors.forename: Volker
authors.initials: V
authors.lastname: Ruppert
authors.forename: Thomas
authors.initials: T
authors.lastname: Meyer
authors.forename: Anna
authors.initials: A
authors.lastname: Balbach
authors.forename: Anette
authors.initials: A
authors.lastname: Richter
authors.forename: Hans-Helge
authors.initials: HH
authors.lastname: Müller
authors.forename: Bernhard
authors.initials: B
authors.lastname: Maisch
authors.forename: Sabine
authors.initials: S
authors.lastname: Pankuweit
mesh_terms: D000328:Adult; D000368:Aged; D001483:Base Sequence; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology / Q000628:therapy / Q000821:virology*; D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D005260:Female; D005838:Genotype; D006321:Heart / Q000821:virology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy / Q000821:virology*; D016732:Parvovirus B19, Human / Q000235:genetics* / Q000276:immunology*; D011446:Prospective Studies; D017422:Sequence Analysis, DNA; D016277:Ventricular Function, Left; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D016756:Immunoglobulins, Intravenous